{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"80.6","value":"25.0"},{"groupId":"OG001","lowerLimit":"0.6","upperLimit":"15.5","value":"4.5"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"52.2","value":"0.0"},{"groupId":"OG003","lowerLimit":"11.9","upperLimit":"54.3","value":"30.0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"45.9","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by the investigator. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG000","title":"Part 2: Intermittent Pemigatinib 9 mg QD"},{"description":"Participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG001","title":"Part 2: Intermittent Pemigatinib 13.5 mg QD"},{"description":"Participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle.","id":"OG002","title":"Part 2: Continuous Pemigatinib 9 mg QD"},{"description":"Participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.","id":"OG003","title":"Part 2: Continuous Pemigatinib 13.5 mg QD"},{"description":"Participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle.","id":"OG004","title":"Part 2: Continuous Pemigatinib 20 mg QD"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Population: all enrolled participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"up to 126 days","title":"Part 2: Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}